CBD Isolate Oral Pain Reliever Formulation for Faster Onset

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing oral pain relievers face challenges such as delayed onset of action, gastrointestinal side effects, liver or kidney toxicity, and risks of dependency or abuse, while alternative methods using cannabinoids have variable effectiveness and side effects.

Innovation Solution

A pharmaceutical composition combining cannabidiol isolate with anti-inflammatory, analgesic, or antipyretic active ingredients, formulated into tablets or capsules, using specific excipients for optimized drug delivery and pharmacokinetic properties.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If traditional oral analgesics (NSAIDs, acetaminophen, ibuprofen, or opioid-based medications) are used, then pain relief is provided, but delayed onset of action and gastrointestinal side effects occur

Engineering Contradiction:

Improvepain relief effectivenessVSAvoidonset of action time

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent combines cannabidiol isolate with traditional analgesic active ingredients to create a composite pharmaceutical formulation. This composite approach leverages the synergistic effects of both cannabinoid and conventional analgesic mechanisms, achieving rapid pain relief without the delayed onset associated with traditional medications alone

Inventive Principle:

Principle #40Composite materials

Solution Approach 2:

The patent modifies pharmacokinetic parameters through optimized formulation techniques, including controlled release mechanisms and enhanced solubility approaches. These parameter changes enable faster absorption and onset of action while maintaining sustained pain relief effects

Inventive Principle:

Principle #35Parameter changes

2Reliability

If traditional oral analgesics are used, then pain relief is achieved, but gastrointestinal side effects and liver or kidney toxicity occur

Engineering Contradiction:

Improvepain relief effectivenessVSAvoidgastrointestinal side effects and organ toxicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

Cannabidiol isolate serves as an intermediary agent that modulates pain through the endocannabinoid system, providing an alternative pain relief pathway that bypasses the gastrointestinal and hepatic metabolism issues associated with traditional NSAIDs and acetaminophen

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The composite formulation combines cannabidiol isolate with traditional analgesics at optimized ratios, allowing the cannabinoid component to reduce the required dosage of conventional medications, thereby minimizing gastrointestinal side effects and organ toxicity while maintaining effective pain relief

Inventive Principle:

Principle #40Composite materials

3Reliability

If opioid-based medications are used, then strong pain relief is provided, but risks of dependency or abuse increase

Engineering Contradiction:

Improvepain relief effectivenessVSAvoiddependency and abuse risk

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

Cannabidiol isolate acts as a non-controlled intermediary substance that provides analgesic effects through cannabinoid receptors, offering a safe alternative to opioids that does not carry the same risk profile for dependency and abuse

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The formulation changes the pharmacological profile from opioid-based to cannabinoid-based pain relief, fundamentally altering the risk parameters regarding dependency and abuse while maintaining effective analgesic outcomes

Inventive Principle:

Principle #35Parameter changes

4Adaptability or versatility

If cannabinoids are used for pain relief, then alternative pain management is provided, but variable effectiveness and side effects occur

Engineering Contradiction:

Improvealternative pain management approachVSAvoideffectiveness consistency

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent uses highly purified cannabidiol isolate with standardized concentrations to eliminate variability in cannabinoid content. This standardization, combined with optimized formulation parameters, ensures consistent bioavailability and reliable pain relief effects across different patients and dosages

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The composite formulation combines cannabidiol isolate with traditional analgesic active ingredients, creating a synergistic effect that enhances and stabilizes the pain relief outcome, reducing the variability and side effects associated with cannabinoid use alone

Inventive Principle:

Principle #40Composite materials

Data Source

PatentUS20250302849A1Oral pain reliever composition, pharmaceutical formulation, and process for making composition and formulation including cannabidiol isolate with select active ingredients

Publication Date: 2025.10.02 CAVENDER MICHAEL

AI summary

A chemical composition for an oral pharmaceutical product is described having a therapeutically effective amount of one or more active pharmaceutical ingredients (API) selected from anti-inflammatory and/or analgesic and/or non-steroidal anti-inflammatory (NSAIDS) and/or antipyretic group(s) of ingredients utilized in combination with a cannabidiol (CBD) isolate.